Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma.
Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Hosing C, et al. Among authors: kebriaei p. Am J Hematol. 2009 Jun;84(6):335-7. doi: 10.1002/ajh.21400. Am J Hematol. 2009. PMID: 19384931 Free PMC article.
Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma.
Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Qazilbash MH, et al. Among authors: kebriaei p. Bone Marrow Transplant. 2007 Mar;39(5):279-83. doi: 10.1038/sj.bmt.1705580. Epub 2007 Jan 29. Bone Marrow Transplant. 2007. PMID: 17262062 Clinical Trial.
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M. Oran B, et al. Among authors: kebriaei p. Biol Blood Marrow Transplant. 2007 Apr;13(4):454-62. doi: 10.1016/j.bbmt.2006.11.024. Epub 2007 Feb 8. Biol Blood Marrow Transplant. 2007. PMID: 17382251 Free PMC article. Clinical Trial.
Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation.
Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E, Khouri IF, Qazilbash M, Anderlini P, Kebriaei P, Popat U, Carrasco-Yalan A, Champlin RE, de Lima M. Oran B, et al. Among authors: kebriaei p. Leukemia. 2007 Dec;21(12):2540-4. doi: 10.1038/sj.leu.2404828. Epub 2007 Jul 5. Leukemia. 2007. PMID: 17611563 No abstract available.
Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Qazilbash MH, et al. Among authors: kebriaei p. Biol Blood Marrow Transplant. 2007 Sep;13(9):1066-72. doi: 10.1016/j.bbmt.2007.05.014. Epub 2007 Jul 16. Biol Blood Marrow Transplant. 2007. PMID: 17697969 Free article.
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.
de Lima M, Champlin RE, Thall PF, Wang X, Martin TG 3rd, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. de Lima M, et al. Among authors: kebriaei p. Leukemia. 2008 Feb;22(2):258-64. doi: 10.1038/sj.leu.2405014. Epub 2007 Nov 8. Leukemia. 2008. PMID: 17989720 Clinical Trial.
382 results